Comparison

AMGEN INC (AMGN) vs Sanofi (SNY)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

AMGN

AMGEN INC

Drug Manufacturers—General

Revenue, FY25: $36.75B
Net income: $7.71B
Operating cash flow: $9.96B
Free cash flow: $8.1B
Net margin: 20.98%
Operating margin: 24.71%
Gross margin: 67.25%

SNY

Sanofi

Drug Manufacturers—General

Revenue, FY25: $43.63B
Net income: $7.81B
Operating cash flow: $10.75B
Free cash flow: $7.21B
Net margin: 17.91%
Operating margin: 14.54%
Gross margin: 77.17%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	AMGN	SNY
Revenue growth, latest filed year	+9.95%	+6.20%
Piotroski F-score	7 of 9	7 of 9
P/E against its own history	about normal	-

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

AMGN

FDA approval
Reimbursement
Cybersecurity
Litigation
China
Tax

And 20 more.

SNY

No 10-K read yet.

Tracked managers holding both

Dodge & Cox Dodge & Cox 0.00% · 0.63%

Updated Sep 17, 2026 · the newer of the two companies' filings